New injection shows promise for tough kidney cancer

NCT ID NCT04169711

Completed Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called ARO-HIF2 in 26 people with advanced clear cell kidney cancer that had gotten worse after other treatments. The main goal was to find a safe dose and check for side effects. This is an early-phase trial, so it focuses on safety and dosing, not yet on curing the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL RENAL CELL CARCINOMA

Contacts and locations

Locations

Research Site 1

Aurora, Colorado, 80045, United States
Research Site 2

Las Vegas, Nevada, 89169, United States
Research Site 4

Nashville, Tennessee, 37232, United States
Research Site 5

Dallas, Texas, 75390, United States
Research Site 6

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.